[{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Reloxaliase","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Reloxaliase","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Allena Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Allena Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allena Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Allena Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

World Vaccine Conference
Not Confirmed
World Vaccine Conference
Not Confirmed

Details : Allena recently completed a Phase 1b multiple ascending dose study of ALLN-346. The study included 18 healthy volunteers, who received either ALLN-346 or placebo (2:1 randomization) for seven days.

Product Name : ALLN-346

Product Type : Enzyme

Upfront Cash : Inapplicable

September 29, 2021

Lead Product(s) : Engineered Urate Oxidase

Therapeutic Area : Rheumatology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

MAGHREB PHARMA
Not Confirmed
MAGHREB PHARMA
Not Confirmed

Details : Allena’s lead product candidate, reloxaliase (formerly ALLN-177), is a first-in-class, non-absorbed, orally-administered enzyme for the treatment of hyperoxaluria.

Product Name : ALLN-177

Product Type : Enzyme

Upfront Cash : Undisclosed

July 14, 2021

Lead Product(s) : Reloxaliase

Therapeutic Area : Gastroenterology

Highest Development Status : Phase III

Sponsor : H.C. Wainwright & Co

Deal Size : $28.0 million

Deal Type : Public Offering

blank

03

World Vaccine Conference
Not Confirmed
World Vaccine Conference
Not Confirmed

Details : Company is developing ALLN-346 for the treatment of hyperuricemia and gout in the setting of advanced CKD, with a Phase 1 multiple ascending dose study recently completed and a Phase 2a program underway.

Product Name : ALLN-346

Product Type : Enzyme

Upfront Cash : Inapplicable

March 11, 2021

Lead Product(s) : Engineered Urate Oxidase

Therapeutic Area : Rheumatology

Highest Development Status : Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

04

World Vaccine Conference
Not Confirmed
World Vaccine Conference
Not Confirmed

Details : Allena now plans to reducing target enrollment to 200 subjects. Conducting earlier interim analysis, expected in Q3 2021.

Product Name : ALLN-177

Product Type : Enzyme

Upfront Cash : Inapplicable

December 02, 2020

Lead Product(s) : Reloxaliase

Therapeutic Area : Nephrology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank